

Pascal Finetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3676099/publications.pdf>

Version: 2024-02-01

67
papers

4,069
citations

218677

26
h-index

118850

62
g-index

68
all docs

68
docs citations

68
times ranked

7315
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature. <i>Cancer Research</i> , 2009, 69, 1302-1313.	0.9	1,067
2	How basal are triple-negative breast cancers?. <i>International Journal of Cancer</i> , 2008, 123, 236-240.	5.1	384
3	Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers. <i>Cancer Research</i> , 2006, 66, 4636-4644.	0.9	273
4	non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. <i>Oncotarget</i> , 2015, 6, 29209-29223.	1.8	193
5	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. <i>Oncolmmunology</i> , 2017, 6, e1253654.	4.6	146
6	Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer. <i>PLoS ONE</i> , 2011, 6, e27656.	2.5	143
7	A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. <i>Nature Medicine</i> , 2017, 23, 568-578.	30.7	131
8	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. <i>Clinical Cancer Research</i> , 2013, 19, 4685-4696.	7.0	130
9	miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. <i>Cell Reports</i> , 2017, 18, 2256-2268.	6.4	111
10	Sixteen Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis. <i>Cancer Research</i> , 2008, 68, 767-776.	0.9	105
11	PDL1 expression is an independent prognostic factor in localized GIST. <i>Oncolmmunology</i> , 2015, 4, e1002729.	4.6	75
12	Comparative genomic analysis of primary tumors and metastases in breast cancer. <i>Oncotarget</i> , 2016, 7, 27208-27219.	1.8	69
13	The Functional Landscape of Hsp27 Reveals New Cellular Processes such as DNA Repair and Alternative Splicing and Proposes Novel Anticancer Targets. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 3585-3601.	3.8	65
14	PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. <i>Oncolmmunology</i> , 2017, 6, e1278100.	4.6	65
15	Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. <i>Molecular Oncology</i> , 2015, 9, 1218-1233.	4.6	64
16	A 25-gene classifier predicts overall survival in resectable pancreatic cancer. <i>BMC Medicine</i> , 2017, 15, 170.	5.5	64
17	PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2. <i>Developmental Cell</i> , 2016, 37, 311-325.	7.0	63
18	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57

#	ARTICLE	IF	CITATIONS
19	High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes. <i>PLoS ONE</i> , 2011, 6, e16950.	2.5	57
20	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 1383-1391.	6.4	54
21	Kinome expression profiling and prognosis of basal breast cancers. <i>Molecular Cancer</i> , 2011, 10, 86.	19.2	46
22	EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. <i>Cancer Letters</i> , 2014, 355, 70-75.	7.2	44
23	Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib. <i>PLoS ONE</i> , 2014, 9, e104302.	2.5	43
24	PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. <i>Oncolmmunology</i> , 2019, 8, e1655362.	4.6	39
25	8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e37943.	2.5	34
26	Sensitive and easy screening for circulating tumor cells by flow cytometry. <i>JCI Insight</i> , 2019, 4, .	5.0	31
27	A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. <i>EMBO Molecular Medicine</i> , 2019, 11, e9930.	6.9	27
28	The therapeutic response of ER+/HER2~ breast cancers differs according to the molecular Basal or Luminal subtype. <i>Npj Breast Cancer</i> , 2020, 6, 8.	5.2	27
29	Enhancement of Breast Cancer Cell Aggressiveness by lncRNA H19 and its Mir-675 Derivative: Insight into Shared and Different Actions. <i>Cancers</i> , 2020, 12, 1730.	3.7	26
30	EFA6B Antagonizes Breast Cancer. <i>Cancer Research</i> , 2014, 74, 5493-5506.	0.9	25
31	Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). <i>Neoplasia</i> , 2017, 19, 564-573.	5.3	25
32	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. <i>Genome Medicine</i> , 2021, 13, 87.	8.2	24
33	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. <i>Molecular Oncology</i> , 2020, 14, 504-519.	4.6	23
34	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2021, 10, 1929724.	4.6	22
35	Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. <i>Cancers</i> , 2021, 13, 2807.	3.7	19
36	Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. <i>Molecular Oncology</i> , 2021, 15, 2752-2765.	4.6	19

#	ARTICLE	IF	CITATIONS
37	The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/ β -Catenin Signaling. <i>Stem Cell Reports</i> , 2018, 11, 1040-1050.	4.8	18
38	Inflammatory breast cancer cells are characterized by abrogated TGF β 1-dependent cell motility and SMAD3 activity. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 385-395.	2.5	18
39	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. <i>Oncotarget</i> , 2018, 9, 33762-33777.	1.8	17
40	PARP1 expression in soft tissue sarcomas is a poor prognosis factor and a new potential therapeutic target. <i>Molecular Oncology</i> , 2019, 13, 1577-1588.	4.6	15
41	Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. , 2022, 10, e003687.		15
42	Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?. <i>Cancers</i> , 2020, 12, 2470.	3.7	14
43	Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC. <i>Cancers</i> , 2020, 12, 689.	3.7	14
44	ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer. <i>British Journal of Cancer</i> , 2019, 120, 931-940.	6.4	13
45	BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells. <i>Cell Death and Disease</i> , 2022, 13, 96.	6.3	13
46	Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1227-1235.	4.1	13
47	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. <i>Clinical Epigenetics</i> , 2019, 11, 141.	4.1	11
48	Neoplastic Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 1889-1902.	3.4	11
49	Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	11
50	Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer. <i>In Vivo</i> , 2020, 34, 177-184.	1.3	10
51	Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2314-2325.	7.0	10
52	Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. <i>Oncogene</i> , 2022, 41, 125-137.	5.9	10
53	Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting. <i>Cancers</i> , 2020, 12, 3058.	3.7	9
54	RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1046-1047.	6.3	9

#	ARTICLE	IF	CITATIONS
55	WEE1 Dependency and Pejorative Prognostic Value in Triple-Negative Breast Cancer. <i>Advanced Science</i> , 2021, 8, e2101030.	11.2	8
56	A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. <i>Cancers</i> , 2019, 11, 1158.	3.7	6
57	LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. <i>Communications Biology</i> , 2021, 4, 987.	4.4	6
58	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. <i>Npj Breast Cancer</i> , 2022, 8, 12.	5.2	6
59	Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients. <i>Cancers</i> , 2022, 14, 932.	3.7	5
60	Wnt/ β -Catenin in GIST Letter. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 327-328.	4.1	4
61	Difference in Therapeutic Response Between Basal and Nonbasal Triple-Negative Breast Cancers. <i>Oncologist</i> , 2013, 18, 1060-1061.	3.7	3
62	CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response. <i>Cancers</i> , 2022, 14, 1306.	3.7	3
63	Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas Letter. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2324-2324.	4.1	2
64	EFA6B regulates a stop signal for collective invasion in breast cancer. <i>Nature Communications</i> , 2021, 12, 2198.	12.8	2
65	CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression. <i>Cancers</i> , 2022, 14, 3356.	3.7	2
66	Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer Letter. <i>Clinical Cancer Research</i> , 2020, 26, 5539-5539.	7.0	0
67	Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial. <i>Cancers</i> , 2022, 14, 2275.	3.7	0